Pheast Therapeutics

About Pheast Therapeutics

Pheast Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically in the field of cancer treatment. The company is focused on developing innovative immunotherapies that target and eliminate cancer cells. Their primary clients are patients suffering from aggressive forms of cancer, such as ovarian and breast cancers.

The company's unique approach involves harnessing the power of macrophages, a type of white blood cell that is part of the body's immune system. Macrophages are known as the first responders of the immune system and have the ability to detect and destroy cancer cells. However, cancer cells often evade these macrophages by expressing "don't eat me" signals. Pheast Therapeutics is developing new drugs, known as innate immune checkpoint inhibitors, to block these signals and allow macrophages to effectively target and eliminate cancer cells.

One of their leading programs is the development of anti-CD24 antibodies. CD24 is a signal highly expressed in ovarian and breast cancers. By blocking this signal, Pheast Therapeutics has observed in preclinical models that macrophages can efficiently target and eliminate cancer cells, leading to tumor clearance over time.

Pheast Therapeutics' business model revolves around the research, development, and eventual commercialization of these novel immunotherapies. The company generates revenue through the sales of these therapies once they have been approved for use in the market.